Nexalin Technology announces issuance of U.S. patent covering HALO Clarity

Nexalin Technology (NXL) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company’s next-generation HALO Clarity neuromodulation device. “This patent represents another important milestone in our mission to transform mental health and neurological care,” said Mark White, Chief Executive Officer of Nexalin. “HALO Clarity is engineered for comfort, usability, and performance to deliver our proprietary DIFS technology – a non-invasive, drug-free approach we believe can meaningfully impact conditions such as depression, anxiety, insomnia, trauma-related disorders, and neurodegenerative diseases including Alzheimer’s and dementia. Importantly, the system is designed for supervised use from the patient’s home, giving physicians the ability to monitor and guide treatment remotely while offering patients a safe and convenient alternative to in-clinic visits. We believe this unique capability has the potential to expand access, improve compliance, and lower the cost of care for patients worldwide.”